Research
Molecular
Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.
Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.
StrongSupportsmedium confidence
Findings suggest that dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.
Why this rating
The review evaluates peer-reviewed literature.
Source
Biochemical and Pharmacological Mechanisms of GLP-1 and Dual Agonists: Implications for Glycemic Control and Cardiovascular Risk Reduction — A Review
Akter Sraboni et al. · Journal of Biochemistry Pharmacology and Public Health · 2026
DOI 10.64907/xkmf.v4.i1.jbpph.1
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.Strong
- Future research should prioritize mechanistic human studies, real-world cardiovascular outcomes, and equity in drug access.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →